341 related articles for article (PubMed ID: 11123433)
1. Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.
Kishimoto S; Miyazawa K; Terakawa Y; Ashikari H; Ohtani A; Fukushima S; Takeuchi Y
Jpn J Cancer Res; 2000 Dec; 91(12):1326-32. PubMed ID: 11123433
[TBL] [Abstract][Full Text] [Related]
2. In vitro antitumor activity, intracellular accumulation, and DNA adduct formation of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum (II) suspended in lipiodol.
Kishimoto S; Miyazawa K; Fukushima S; Takeuchi Y
Jpn J Cancer Res; 2000 Jan; 91(1):99-104. PubMed ID: 10744050
[TBL] [Abstract][Full Text] [Related]
3. In vitro cytotoxicity of cis[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum(II) suspended in lipiodol in rat hepatoma AH-109A cells and human tumor cell lines.
Kishimoto S; Noguchi T; Yamaoka T; Fukushima S; Takeuchi Y
Biol Pharm Bull; 2000 Apr; 23(4):487-91. PubMed ID: 10784433
[TBL] [Abstract][Full Text] [Related]
4. Relation between intracellular accumulation and cytotoxic activity of cis-[((1R, 2R)-1, 2-cyclohexanediamine-N, N')bis(myristato)]platinum(II) suspended in Lipiodol.
Kishimoto S; Ohtani A; Fukuda H; Fukushima S; Takeuchi Y
Biol Pharm Bull; 2003 May; 26(5):683-6. PubMed ID: 12736512
[TBL] [Abstract][Full Text] [Related]
5. In vitro release of SM-11355, cis[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum(II) suspended in lipiodol.
Kishimoto S; Noguchi T; Yamaoka T; Fukushima S; Takeuchi Y
Biol Pharm Bull; 2000 May; 23(5):637-40. PubMed ID: 10823679
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration.
Kishimoto S; Noguchi T; Yamaoka T; Fukushima S; Takeuchi Y
Biol Pharm Bull; 2000 Mar; 23(3):344-8. PubMed ID: 10726891
[TBL] [Abstract][Full Text] [Related]
7. Intracellular uptake of an antitumor-active azole-bridged dinuclear platinum(II) complex in cisplatin-resistant tumor cells.
Kishimoto S; Yasuda M; Suzuki R; Fukushima S
Biometals; 2016 Dec; 29(6):1075-1083. PubMed ID: 27787693
[TBL] [Abstract][Full Text] [Related]
8. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
9. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
Kido Y; Khokhar AR; al-Baker S; Siddik ZH
Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
[TBL] [Abstract][Full Text] [Related]
10. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
11. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
Mellish KJ; Kelland LR; Harrap KR
Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
[TBL] [Abstract][Full Text] [Related]
12. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
13. Role of Na+, K+-ATPase alpha1 subunit in the intracellular accumulation of cisplatin.
Kishimoto S; Kawazoe Y; Ikeno M; Saitoh M; Nakano Y; Nishi Y; Fukushima S; Takeuchi Y
Cancer Chemother Pharmacol; 2006 Jan; 57(1):84-90. PubMed ID: 16044341
[TBL] [Abstract][Full Text] [Related]
14. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
[TBL] [Abstract][Full Text] [Related]
15. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis.
Hanada M; Baba A; Tsutsumishita Y; Noguchi T; Yamaoka T; Chiba N; Nishikaku F
Cancer Chemother Pharmacol; 2009 Aug; 64(3):473-83. PubMed ID: 19104812
[TBL] [Abstract][Full Text] [Related]
16. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
17. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C
Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475
[TBL] [Abstract][Full Text] [Related]
18. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line.
Esaki T; Nakano S; Masumoto N; Fujishima H; Niho Y
Int J Cancer; 1996 Feb; 65(4):479-84. PubMed ID: 8621231
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of an acquired cisplatin-resistant subline in a human osteosarcoma cell line.
Asada N; Tsuchiya H; Ueda Y; Tomita K
Anticancer Res; 1998; 18(3A):1765-8. PubMed ID: 9673402
[TBL] [Abstract][Full Text] [Related]
20. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.
Bible KC; Boerner SA; Kirkland K; Anderl KL; Bartelt D; Svingen PA; Kottke TJ; Lee YK; Eckdahl S; Stalboerger PG; Jenkins RB; Kaufmann SH
Clin Cancer Res; 2000 Feb; 6(2):661-70. PubMed ID: 10690552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
